ProPhase Labs, Inc. (PRPH)
| Market Cap | 1.15M -91.8% |
| Revenue (ttm) | 4.90M -27.6% |
| Net Income | -13.35M |
| EPS | -1.57 |
| Shares Out | 9.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,188 |
| Average Volume | 106,955 |
| Open | 0.1280 |
| Previous Close | 0.1200 |
| Day's Range | 0.1200 - 0.1399 |
| 52-Week Range | 0.0680 - 6.6590 |
| Beta | 0.17 |
| RSI | 47.88 |
| Earnings Date | May 15, 2026 |
About ProPhase Labs
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, inc... [Read more]
Financial Performance
In 2025, ProPhase Labs's revenue was $4.90 million, a decrease of -27.62% compared to the previous year's $6.77 million. Losses were -$13.35 million, -74.98% less than in 2024.
Financial StatementsNews
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
$201.2 Million in Gross Claims with Expanding Settlement Activity Across Multiple Insurance Carriers Active Negotiations Support Estimated $50–$60 Million Net Recovery and Near-Term Cash Flow Potentia...
ProPhase Labs says Crown Medical Collections effort ‘continues to advance’
ProPhase Labs (PRPH) provided a business update regarding its Crown Medical Collections initiative and related strategic activities. The Company reported that its Crown Medical Collections effort cont...
ProPhase Labs initiates potential sale, partnership for BE-Smart
ProPhase Labs (PRPH) announced that it has initiated a potential sale or strategic partnership process for BE-Smart, its clinically validated esophageal cancer risk stratification test, and is advanci...
ProPhase Labs provides Crown Medical Collections update
ProPhase Labs (PRPH) provided an operational update on the progress of its Crown Medical Collections initiative relating to legacy COVID-19 testing receivables held by its laboratory subsidiaries curr...
ProPhase Labs uplists from Pink Sheets to OTC Market
ProPhase Labs (PRPH) announced that its common stock has been approved and uplisted from the Pink Sheets to the OTC market.
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company's un...
ProPhase Labs trading halted, news pending
19:50 EST ProPhase Labs (PRPH) trading halted, news pending
ProPhase Labs Transcript: Status Update
A merger LOI with ABL aims to unlock synergies and value, with current shareholders set to benefit from a $10 million carve-out and Crown Medical collections. Key assets include a profitable genomics business and a high-potential cancer test, while NASDAQ compliance is being maintained.
Why Is Prophase Labs Stock (PRPH) Up Today?
Prophase Labs stock saw a massive rally on Friday alongside its plans for a reverse merger.
ProPhase Labs signs non-binding LOI for proposed reverse merger with ABL
ProPhase Labs (PRPH) and Advanced Biological Laboratories entered into a non-binding Letter of Intent regarding a proposed reverse merger transaction pursuant to which ABL would become the majority ow...
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company.
ProPhase Labs Transcript: Status Update
Crown Medical Collections is expected to deliver over $50 million in near-term cash, supporting a turnaround after significant cost reductions and asset restructuring. The company is ready to commercialize its BE-Smart cancer test and expand its genomics business, with multiple financing and M&A options under consideration.
Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on December 1
UNIONDALE, NY, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET. The exclusive event, hosted by Red...
ProPhase Labs Earnings Call Transcript: Q3 2025
Management expects significant cash inflows from Crown Medical Collections to transform the financial position, with additional upside from BE-Smart Esophageal Cancer Test and Nebula Genomics. Strategic initiatives, including potential M&A and share buybacks, are contingent on maintaining Nasdaq compliance and successful proxy voting.
ProPhase Labs reports Q3 EPS (16c) vs. (26c) last year
Reports Q3 revenue $0.9M vs. $1.4M last year.”The public markets are not yet reflecting the true value of ProPhase or the multi-year opportunities now in front of us,” said Ted
ProPhase Labs in M&A discussions not connected to crypto treasury strategy
ProPhase Labs (PRPH) announced it is in M&A related discussions not connected to a crypto treasury strategy. These discussions, if successful, could potentially recognize the underlying value of ProPh...
ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.
ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically Important.
ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19
UNIONDALE, NY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today tha...
ProPhase Labs urges shareholders to vote ‘FOR’ all proposed resolutions
ProPhase Labs (PRPH) reminds shareholders of record as of October 20, 2025, of the Company’s upcoming Special Meeting of Stockholders, which will be held on November 24, 2025. The company
ProPhase Labs Urges Shareholders to Vote by November 23 on Proxy Proposals
UNIONDALE, NY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) reminds shareholders of record as of October 20, 2025, of the Company's upcoming Special Meeting of Stockholders, wh...
ProPhase Labs Transcript: 2025 ThinkEquity Conference
Three core assets—COVID testing collections, a novel esophageal cancer test, and Nebula Genomics—are positioned for significant value creation. Legal action is expected to recover $50M in cash within months, while the cancer test's recent journal publication paves the way for commercialization and potential multi-billion dollar market impact.
ProPhase Labs announces publication of BE-Smart Esophageal Cancer study
ProPhase Labs (PRPH) announced that its study, “Assessing Risk of Progression in Barrett’s Esophagus Using a Mass-Spectrometry-Based Proteomic Panel,” has been published online in Clinical and Transla...
ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology
Peer-Reviewed Study Conducted in Collaboration with Mayo Clinic Demonstrates 100% Sensitivity and Strong Predictive Power for Esophageal Cancer Progression
ProPhase Labs engages RedChip to lead investor relations efforts
ProPhase Labs (PRPH) engaged RedChip Companies to lead its investor relations efforts. RedChip will employ its comprehensive, multi-channel investor relations platform, including global digital distri...
ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts
UNIONDALE, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced t...